To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Amneal Pharmaceuticals (NasdaqGS:AMRX) Q4 2025 Earnings call February 27, 2026 08:30 AM ET Company ParticipantsAnastasios Konidaris - EVP and CFOAnthony DiMeo - Head of Investor RelationsChintu Patel - Co-Founder and Co-CEOChirag Patel - Co-Founder and Co-CEOChris Schott - Managing DirectorJoe Renda - SVP and Chief Commercial OfficerConference Call ParticipantsDavid Amsellem - Managing Director and Senior Research AnalystLeszek Sulewski - Research AnalystMatt Dellatorre - VP and Equity AnalystOperatorThank ...

Amneal Pharmaceuticals (NasdaqGS:AMRX) Q4 2025 Earnings call February 27, 2026 08:30 AM ET Company ParticipantsAnastasios Konidaris - EVP and CFOAnthony DiMeo - Head of Investor RelationsChintu Patel - Co-Founder and Co-CEOChirag Patel - Co-Founder and Co-CEOChris Schott - Managing DirectorJoe Renda - SVP and Chief Commercial OfficerConference Call ParticipantsDavid Amsellem - Managing Director and Senior Research AnalystLes Sulewski - AnalystMatt Dellatorre - VP and Equity AnalystOperatorThank you all for ...

Amneal Pharmaceuticals (NasdaqGS:AMRX) Q4 2025 Earnings call February 27, 2026 08:30 AM ET Speaker8Thank you all for your patience. The conference call titled Amneal Pharmaceuticals Fourth Quarter and Full Year 2025 Earnings Call will begin shortly. During the presentation, you'll have the opportunity to ask a question by pressing Star followed by the number one on your telephone keypads. Again, please stand by and we will begin in a few minutes. Good morning. Welcome to the Amneal Pharmaceuticals Fourth Qu ...

Amneal Pharmaceuticals Q4 2025 Earnings Call Cautionary statement on forward looking statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management's intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future opera ...

Core Viewpoint - Amneal Pharmaceuticals reported quarterly earnings of $0.21 per share, exceeding the Zacks Consensus Estimate of $0.18 per share, and showing an increase from $0.12 per share a year ago, resulting in an earnings surprise of +18.85% [1] Financial Performance - The company achieved revenues of $814.32 million for the quarter ended December 2025, which was slightly below the Zacks Consensus Estimate by 0.19%, but an increase from $730.52 million year-over-year [2] - Over the last four quarters, Amneal has surpassed consensus EPS estimates four times, but has only topped consensus revenue estimates once [2] Stock Performance - Amneal shares have increased approximately 15% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.9% [3] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.22 on revenues of $753.87 million, and for the current fiscal year, it is $0.96 on revenues of $3.21 billion [7] - The estimate revisions trend for Amneal was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Drugs industry, to which Amneal belongs, is currently ranked in the bottom 45% of over 250 Zacks industries, suggesting that the overall industry outlook may impact stock performance [8]

Exhibit 99.1 AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS ‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth – ‒ Q4 2025 Net Revenue of $814 million; GAAP Net Income of $35 million; Diluted Income per Share of $0.11 ‒ ‒ Q4 2025 Adjusted Net Income of $68 million, Adjusted EBITDA of $175 million; Adjusted Diluted EPS of $0.21 ‒ ‒ Full Year 2025 Net Revenue of $3.02 billion; GAAP Net Income of $72 million; Diluted Income per Share o ...

Core Insights - Amneal Pharmaceuticals reported strong financial performance for the full year 2025, meeting or exceeding all guidance metrics, with expectations for continued growth in 2026 [1][2] Financial Performance - Q4 2025 net revenue was $814 million, an 11% increase from $731 million in Q4 2024 [3] - Full year 2025 net revenue reached $3.02 billion, an 8% increase from $2.79 billion in 2024 [4] - Q4 2025 GAAP net income was $35 million, compared to a net loss of $31 million in Q4 2024 [3] - Full year 2025 GAAP net income was $72 million, a significant recovery from a net loss of $117 million in 2024 [4] Adjusted Financial Metrics - Q4 2025 adjusted net income was $68 million, with adjusted EBITDA of $175 million, reflecting a 13% increase from Q4 2024 [3] - Full year 2025 adjusted EBITDA was $688 million, a 10% increase compared to the previous year [4] - Adjusted diluted EPS for Q4 2025 was $0.21, up from $0.12 in Q4 2024 [3] - Full year 2025 adjusted diluted EPS was $0.83, compared to $0.58 in 2024 [4] Business Segments Performance - Specialty segment revenue grew by 38% in Q4 2025, driven by products like CREXONT® and UNITHROID® [3] - Affordable Medicines segment revenue decreased by 1% due to timing issues with key products [3] - AvKARE segment revenue increased by 24%, attributed to growth in government label sales [3] 2026 Financial Guidance - The company provided guidance for 2026, projecting net revenue between $3.05 billion and $3.15 billion, adjusted EBITDA between $720 million and $760 million, and adjusted diluted EPS between $0.93 and $1.03 [1][6][7] - Affordable Medicines net revenue is expected to grow by 7% to 8%, while Specialty revenue is projected to remain flat year-over-year [7]

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is among the 7 Cheap Pharmaceutical Stocks to Buy According to Hedge Funds. Amneal Pharmaceuticals, Inc. (AMRX) Added to S&P SmallCap 600 Index, Boosting Investor Visibility The next stock on our list is Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX). TheFly reported on Feb 11 that JP Morgan raised AMRX price target by $4 and maintained a Buy rating. Separately, on January 29, Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) announced that it would be added to the S&P S ...

Core Insights - The article emphasizes the importance of the Zacks Rank system, which focuses on earnings estimates and revisions to identify strong stocks [1] - Value investing is highlighted as a popular strategy for finding undervalued companies based on fundamental analysis [2] Company Analysis: Amneal Pharmaceuticals (AMRX) - Amneal Pharmaceuticals is currently rated with a Zacks Rank 2 (Buy) and has an A grade for Value, making it a notable stock for value investors [3] - The company has a Price-to-Sales (P/S) ratio of 1.55, significantly lower than the industry average of 4.46, indicating potential undervaluation [4] - Amneal's Price-to-Cash Flow (P/CF) ratio stands at 10.89, compared to the industry average of 14.01, further supporting the notion of being undervalued [5] - Over the past 12 months, AMRX's P/CF has fluctuated between a high of 61.60 and a low of 8.57, with a median of 16.33, showcasing its cash flow performance [5] - Overall, the metrics suggest that Amneal Pharmaceuticals is likely undervalued, and its strong earnings outlook positions it as one of the market's strongest value stocks [6]